Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: Comparison with microsomes for Ki determination

Drug Metabolism and Disposition

Volumn 35, Issue 11, 2007, Pages 2119-2126

  Brown, Hayley S ^a   Chadwick, Anthony ^a,b   Houston, J Brian ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C; CYTOCHROME P450 2D; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; DEXTROMETHORPHAN; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; KETOCONAZOLE; MICONAZOLE; MIDAZOLAM; PHENYTOIN; QUININE; TOLBUTAMIDE;

ANIMAL EXPERIMENT; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DRUG METABOLISM; IN VITRO STUDY; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CATALYSIS; CELLS, CULTURED; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; ENZYME INHIBITORS; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; HEPATOCYTES; KETOCONAZOLE; KINETICS; MALE; MICONAZOLE; MICROSOMES, LIVER; MIDAZOLAM; PHENYTOIN; QUININE; RATS; RATS, SPRAGUE-DAWLEY; TOLBUTAMIDE;

RATTUS;

EID: 35548948469     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017095     Document Type: Article

References (40)

1. Ashforth EIL, Carlile DJ, Chenery R, and Houston JB (1995) Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. J Pharmacol Exp Ther 274:761-766.
2. Austin RP, Barton P, Mohmed S, and Riley RJ (2005) The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab Dispos 33:419-425.
3. Berry MN and Friend DS (1969) High-yield preparation of isolated rat liver parenchymal cells. A biochemical and fine structural study. J Cell Biol 43:506-520.
4. Brown HS, Galetin A, Hallifax D, and Houston JB (2006) Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 45:1035-1050.
5. Brown HS, Griffin M, and Houston JB (2007) Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35:293-301.
6. Brown HS, Ito K, Galetin A, and Houston JB (2005) Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508-518.
7. Busch AE, Quester S, Ulzheimer JC, Waldegger S, Gorboulev V, Arndt P, Lang F, and Koepsell H (1996) Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J Biol Chem 271:32599-32604.
8. Carlile DJ, Stevens AJ, Ashforth EI, Waghela D, and Houston JB (1998) In vivo clearance of ethoxycoumarin and its prediction from in vitro systems. Use of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes. Drug Metab Dispos 26:216-221.
9. Chovan JP, Ring SC, Yu E, and Baldino JP (2007) Cytochrome P450 probe substrate metabolism kinetics in Sprague Dawley rats. Xenobiotica 37:459-473.
10. Daniel WA (2003) Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions. Prog Neuropsychopharmacol Biol Psychiatry 27:65-73.
11. Di Marco A, Yao D, and Laufer R (2003) Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes: kinetics and sensitivity to cytochrome P450 2D6 inhibitors. Eur J Biochem 270:3768-3777.
12. Engtrakul JJ, Foti RS, Strelevitz TJ, and Fisher MB (2005) Altered AZT glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment. Drug Metab Dispos 33:1621-1627.
13. Ghosal A, Satoh H, Thomas PE, Bush E, and Moore D (1996) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA expressed human cytochrome P450. Drug Metab Dispos 24:940-947.
14. Griffin SJ and Houston JB (2004) Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance. Drug Metab Dispos 32:552-558.
15. Hallifax D and Houston JB (2006) Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for the prediction of in vivo metabolic clearance. Drug Metab Dispos 35:1829-1836.
16. Hallifax D and Houston JB (2007) Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction. Drug Metab Dispos 35:1325-1332.
17. Hallifax D, Rawden HC, Hakooz N, and Houston JB (2005) Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines. Drug Metab Dispos 33:1852-1858.
18. Hayes KA, Brennan B, Chenery R, and Houston JB (1995) In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data. Drug Metab Dispos 23:349-353.
19. Hewitt NJ, Lechon MJG, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GMM, and Hengstler JG (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance and hepatotoxicity studies. Drug Metab Rev 39:159-234.
20. Ito K, Brown HS, and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-86. Erratum 58:565-568.
21. Ito K, Chiba K, Horikawa M, Ishigami M, Mizuno N, Aoki J, Gotoh Y, Iwatsubo T, Kanamitsu S, Kato M, Kawahara I, Niinuma K, Nishino A, Sato N, Tsukamoto Y, Ueda K, Itoh T, and Sugiyama Y (2002) Which concentration of inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS Pharm Sci 4:1-8.
22. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, and Sugiyama Y (1998a) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38:461-499.
23. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998b) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-411.
24. Jones HM, Hallifax D, and Houston JB (2004) Quantitative prediction of the in vivo inhibition of diazepam metabolism by omeprazole using rat liver microsomes and hepatocytes. Drug Metab Dispos 32:572-580.
25. Kobayashi K, Urashima K, Shimada N, and Chiba K (2003) Selectivities of human cytochrome P450 inhibitors towards rat P450 isoforms: study with cDNA-expressed systems of the rat. Drug Metab Dispos 31:833-836.
26. Kouzuki H, Suzuki H, Ito K, Ohashi R, and Sugiyama Y (1999) Contribution of organic anion transporting polypeptides to uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther 288:627-634.
27. Lau YY, Sapidou E, Cui X, White RE, and Cheng KC (2002) Development of a novel in vitro method to predict hepatic clearance using fresh, cryopreserved and sandwich-cultured hepatocytes. Drug Metab Dispos 30:1446-1454.
28. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rudhmore TH, and Shou M (2001) Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos 29:368-374.
29. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
30. Mano Y, Usui T and Kamimura H (2007) Comparison of inhibition potentials of drugs against zidovudine glucuronidation in rat hepatocytes and liver microsomes. Drug Metab Dispos 35:602-606.
31. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
32. Shibata Y, Takahashi H, Chiba M, and Ishii Y (2002) Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab Dispos 30:892-896.
33. Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390.
34. Soucek P and Gut I (1992) Cytochromes P450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 22:83-103.
35. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, and Shader RI (1994) Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 268:1278-1283.
36. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, and Shader RI (1995) Inhibition of Alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15:125-131.
37. Witherow LE and Houston JB (1999) Sigmoidal kinetics of CYP3A substrates: An approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. J Pharmacol Exp Ther 290:58-65.
38. Worboys PD, Brennan B, Bradbury A, and Houston JB (1996) Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition. Xenobiotica 26:897-907.
39. Wu CY and Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharmacol Res 22:11-23.
40. Yamano K, Yamamoto K, Kotaki H, Sawada Y, and Iga T (1999) Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver. Drug Metab Dispos 27:395-402.